FDA Brief

Warning letters Drugs

FDA warning letter to

Belmar Pharma Solutions, Drug Depot, LLC., dba APS Pharmacy

MediumIssued Mar 31, 2023Posted Apr 18, 2023Division of Pharmaceutical Quality Operations II

FDA warns Drug Depot dba APS Pharmacy over compounded drugs made with ineligible bulk substances.

What happened

FDA inspected Drug Depot, LLC dba APS Pharmacy in Palm Harbor, Florida, from June 6 to June 17, 2022. Investigators found the firm compounded drug products using bulk drug substances that failed section 503A conditions: the substances lacked applicable USP/NF monographs or approved-drug status and were not on the 503A bulks list, and some were made by establishments not registered under section 510 of the FDCA. FDA also said the firm's responses to the Form FDA 483 (inspection findings) did not address these issues.

What FDA found

  1. The firm compounded drugs with bulk drug substances that are not the subject of a USP or NF monograph, are not components of FDA-approved drugs, and are not on the 503A bulks list.

    FDCA section 503A(b)(1)(A)(i) [21 U.S.C. § 353a]
  2. The firm used bulk drug substances made by establishments not registered under section 510 of the FDCA.

    FDCA section 503A(b)(1)(A)(ii) [21 U.S.C. § 360]
  3. Because the compounded products did not qualify for section 503A exemptions, they were unapproved new drugs without FDA-approved applications.

    FDCA sections 505(a) and 301(d) [21 U.S.C. §§ 355(a), 331(d)]
  4. The products' labeling lacked adequate directions for use for conditions not suitable for self-diagnosis and treatment, making them misbranded.

    FDCA section 502(f)(1) [21 U.S.C. § 352(f)(1)]

What FDA wants

FDA asks the company to notify it in writing within 15 working days of the steps taken to correct the violations and prevent recurrence, including supporting documents. If it cannot fully address the matter in that time, it must explain the delay and give a completion date.

Who should pay attention

  • compounding pharmacies that use bulk drug substances
  • healthcare providers who purchase compounded drugs
  • bulk ingredient suppliers verifying registration status

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Nanjing Hanxin Pharmaceutical Technology Co. Ltd.

    FDA warns Nanjing Hanxin of drug-ingredient quality failures and poor supplier oversight; its drugs face U.S. import detention.

    High risk
  2. Chongqing Qiancan Technology Co., Ltd.

    Chongqing Qiancan Technology, an API maker in China, refused FDA records requests; FDA placed its drugs on import alert 66-79.

    High risk
  3. Tianjin Healthcare Medical Technology Co., Ltd.

    Chinese API maker refused FDA records requests, and all its drugs now face a US import alert.

    High risk
  4. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low